Emily R.M. Sydnor Spivak
No Rating Available
(Learn About Our Rating System)

Emily R.M. Sydnor Spivak, MD, MHS

Languages spoken: English

Clinical Locations

University of Utah Hospital

Infectious Diseases, Area E
Salt Lake City
801-585-2031

  • Dr. Spivak is an Associate Professor of Medicine in the Division of Infectious Diseases. She established and serves as Co-Director of the Antimicrobial Stewardship Programs at University of Utah Health and the Salt Lake City Veterans Affairs Healthcare System. She completed her residency and fellowship training at the Johns Hopkins University School of Medicine and earned a Masters in Health Sciences in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health.

    Dr. Spivak's research interests focus on understanding patterns and drivers of antimicrobial use, methods to assess appropriateness, and development and evaluation of methods to improve antimicrobial use. She has led clinical research focused on evaluating patient outcomes related to various antibiotic use strategies. She is also involved with national Veterans Affairs efforts to evaluate antimicrobial use, develop tools to improve use and dissemination and evaluation of these resources.

    She is a member of the Society of Healthcare Epidemiology (SHEA) where she serves on the Public Policy and Government Affairs Committee and the Antibiotic Stewardship Committee. She is a Fellow of the Infectious Diseases Society of America (IDSA), and serves as Vice Chair of the IDSA Antimicrobial Resistance Committee. She also serves as a member of the Board of Scientific Counselors to the Office of Infectious Diseases at the Centers for Disease Control and Prevention, and is Co-Chair of the Vizient Antimicrobial Stewardship Committee.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Infectious Disease)

  • Dr. Spivak is an Associate Professor of Medicine in the Division of Infectious Diseases. She established and serves as Co-Director of the Antimicrobial Stewardship Programs at University of Utah Health and the Salt Lake City Veterans Affairs Healthcare System. She completed her residency and fellowship training at the Johns Hopkins University School of Medicine and earned a Masters in Health Sciences in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health.

    Dr. Spivak's research interests focus on understanding patterns and drivers of antimicrobial use, methods to assess appropriateness, and development and evaluation of methods to improve antimicrobial use. She has led clinical research focused on evaluating patient outcomes related to various antibiotic use strategies. She is also involved with national Veterans Affairs efforts to evaluate antimicrobial use, develop tools to improve use and dissemination and evaluation of these resources.

    She is a member of the Society of Healthcare Epidemiology (SHEA) where she serves on the Public Policy and Government Affairs Committee and the Antibiotic Stewardship Committee. She is a Fellow of the Infectious Diseases Society of America (IDSA), and serves as Vice Chair of the IDSA Antimicrobial Resistance Committee. She also serves as a member of the Board of Scientific Counselors to the Office of Infectious Diseases at the Centers for Disease Control and Prevention, and is Co-Chair of the Vizient Antimicrobial Stewardship Committee.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor (Clinical)
    Academic Divisions Infectious Diseases
    Board Certification
    American Board of Internal Medicine (Sub: Infectious Disease)

    Education history

    Graduate Training Clinical Investigation - Johns Hopkins Bloomberg School of Public Health M.H.S.
    Chief Resident Internal Medicine - Osler Medical Service, Johns Hopkins University School of Medicine Chief Resident
    Fellowship Infectious Diseases - Johns Hopkins University School of Medicine Fellow
    Residency Internal Medicine - Johns Hopkins University School of Medicine Resident
    Internship Internal Medicine - Beth Israel Deaconess Medical Center Intern
    Professional Medical Medicine - University of Virginia School of Medicine M.D.
    Undergraduate Biology - The College of William and Mary B.S.

    Selected Publications

    Journal Article

    1. Doernberg SB, Heil EL, Fiawoo S, Lee JH, Cosgrove SE, Dobrzynski DM, Li Y, Shields RK, Spivak ES, Stohs EJ, Tamma PD, McCreary EK (2025). Epidemiology, Treatment, and Outcomes of Gram-Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients. Clin Transplant, 39(4), e70160. (Read full article)
    2. Gray J, Zhang C, Earl A, Spivak ES (2025). Short versus long treatment duration for streptococcal bloodstream infection. Antimicrob Steward Healthc Epidemiol, 5(1), e47. (Read full article)
    3. Payne J, Sutton JD, Blackburn BE, Bansod S, Imlay H, Spivak ES, Pupaibool J, Gililland JM, Certain LK (2025). Effect of oral antibiotics after two-stage revision for periprosthetic joint infection on subsequent antibiotic resistance within a national cohort of United States veterans. J Bone Jt Infect, 10(1), 7-14. (Read full article)
    4. Fabre V, Hsu YJ, Carroll KC, Salinas AB, Gadala A, Bower C, Boyd S, Degnan KO, Dhaubhadel P, Diekema DJ, Drees M, Feeser B, Fisher MA, Flynn C, Ford B, Gettler EB, Glaser LJ, Howard-Anderson J, Johnson JK, Kim JJ, Martinez M, Mathers AJ, Mermel LA, Moehring RW, Nelson GE, OHoro JC, Pepe DE, Robinson ED, Rodrguez-Nava G, Ryder JH, Salinas JL, Schrank GM, Shah A, Shelly M, Spivak ES, Stewart KO, Talbot TR, Van Schooneveld TC, Wasylyshyn A, Cosgrove SE, Centers for Disease Control and Prevention CDC Prevention Epicenters Program (2025). Blood Culture Use in Medical and Surgical Intensive Care Units and Wards. JAMA Netw Open, 8(1), e2454738. (Read full article)
    5. Imlay H, Ciarkowski CE, Bryson-Cahn C, Chan JD, Hartlage WP, Hersh AL, Lynch JB, Martinez-Paz N, Spivak ES, Hardin H, White AT, Wu C, Kassamali Escobar Z, Vaughn VM (2024). Validation and generalizability of an asymptomatic bacteriuria metric in critical access hospitals. Infect Control Hosp Epidemiol, 1-6. (Read full article)
    6. Ciarkowski CE, Imlay HN, Bryson-Cahn C, Chan JD, Hartlage W, Hersh AL, Lynch JB, Martinez-Paz N, Spivak ES, Hardin H, White AT, Wu C, Vaughn VM, Kassamali Escobar Z (2024). Antimicrobial stewardship to reduce overtreatment of asymptomatic bacteriuria in critical access hospitals: measuring a quality improvement intervention. Infect Control Hosp Epidemiol, 1-7. (Read full article)
    7. Kwon JH, Advani SD, Branch-Elliman W, Braun BI, Cheng VC, Chiotos K, Douglas P, Gohil SK, Keller SC, Klein EY, Krein SL, Lofgren ET, Merrill K, Moehring RW, Monsees E, Perri L, Scaggs Huang F, Shelly MA, Skelton F, Spivak ES, Sreeramoju PV, Suda KJ, Ting JY, Weston GD, Yassin MH, Ziegler MJ, Mody L (2024). A call to action: the SHEA research agenda to combat healthcare-associated infections. Infect Control Hosp Epidemiol, 45(9), 1-18. (Read full article)
    8. Imlay H, Greenlee SB, Tritle BJ, Fino NF, Spivak ES (2024). In-person prospective audit and feedback on an oncology ward: development of an immunocompromised antimicrobial stewardship program. Antimicrob Steward Healthc Epidemiol, 4(1), e173. (Read full article)
    9. Spivak ES, Tobin J, Hersh AL, Lee AP (2024). Greenhouse gas emissions due to unnecessary antibiotic prescriptions. Antimicrob Steward Healthc Epidemiol, 4(1), e114. (Read full article)
    10. Vaughn VM, Krein SL, Hersh AL, Buckel WR, White AT, Horowitz JK, Patel PK, Gandhi TN, Petty LA, Spivak ES, Bernstein SJ, Malani AN, Johnson LB, Neetz RA, Flanders SA, Galyean P, Kimball E, Bloomquist K, Zickmund T, Zickmund SL, Szymczak JE (2023). Excellence in Antibiotic Stewardship: A Mixed-Methods Study Comparing High-, Medium-, and Low-Performing Hospitals. Clin Infect Dis, 78(6), 1412-1424. (Read full article)
    11. Wimmer MR, Griffin M, Peterson-Weber A, Schulz LT, Hamel AG, Schwei RJ, Fong K, Burgess DR, Brett M, Hale CM, Holubar M, Jain R, Larry R, Spivak ES, Newland H, Njoku J, Postelnick M, Walraven C, Pulia MS (2023). Diagnostic testing and antibiotic utilization among inpatients evaluated for coronavirus disease 2019 (COVID-19) pneumonia. Infect Control Hosp Epidemiol, 45(5), 667-669. (Read full article)
    12. Hersh AL, Stenehjem EA, Fino N, Spivak ES (2024). Impact of COVID-19 on urgent care diagnoses and the new AXR metric. Antimicrob Steward Healthc Epidemiol, 4(1), e49. (Read full article)
    13. Park HS, Yin A, Barranta C, Lee JS, Caputo CA, Sachithanandham J, Li M, Yoon S, Sitaras I, Jedlicka A, Eby Y, Ram M, Fernandez RE, Baker OR, Shenoy AG, Mosnaim GS, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Lau B, Ehrhardt S, Baksh SN, Shapiro JR, Ou J, Na YB, Knoll MD, Ornelas-Gatdula E, Arroyo-Curras N, Gniadek TJ, Caturegli P, Wu J, Ndahiro N, Betenbaugh MJ, Ziman A, Hanley DF, Casadevall A, Shoham S, Bloch EM, Gebo KA, Tobian AA, Laeyendecker O, Pekosz A, Klein SL, Sullivan DJ (2024). Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. JCI Insight, 9(8). (Read full article)
    14. Park HS, Yin A, Barranta C, Lee JS, Caputo CA, Sachithanandham J, Li M, Yoon S, Sitaras I, Jedlicka A, Eby Y, Ram M, Fernandez RE, Baker OR, Shenoy AG, Mosnaim GS, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Lau B, Ehrhardt S, Baksh SN, Shapiro JR, Ou J, Na YB, Knoll MD, Ornelas-Gatdula E, Arroyo-Curras N, Gniadek TJ, Caturegli P, Wu J, Ndahiro N, Betenbaugh MJ, Ziman A, Hanley DF, Casadevall A, Shoham S, Bloch EM, Gebo KA, Tobian AAR, Laeyendecker O, Pekosz A, Klein SL, Sullivan DJ (2023). Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. (Read full article)
    15. Earl A, Greenlee S, Fong K, Imlay H, Spivak ES (2023). Positivity of repeat nasal MRSA PCR screening: a single-center experience. Antimicrob Steward Healthc Epidemiol, 3(1), e226. (Read full article)
    16. Shulder S, Tamma PD, Fiawoo S, Dzintars K, Escobar D, Livorsi DJ, Malani AN, Palacio D, Spivak ES, Zimmerman M, Bork JT (2023). Infectious Diseases Consultation Associated With Reduced Mortality in Gram-Negative Bacteremia. Clin Infect Dis, 77(9), 1234-1237. (Read full article)
    17. Huaman MA, Raval JS, Paxton JH, Mosnaim GS, Patel B, Anjan S, Meisenberg BR, Levine AC, Marshall CE, Yarava A, Shenoy AG, Heath SL, Currier JS, Fukuta Y, Blair JE, Spivak ES, Petrini JR, Broderick PB, Rausch W, Cordisco M, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Kassaye SG, Ram M, Wang Y, Das P, Lane K, McBee NA, Gawad AL, Karlen N, Ford DE, Laeyendecker O, Pekosz A, Klein SL, Ehrhardt S, Lau B, Baksh SN, Shade DM, Casadevall A, Hanley DF, Ou J, Gniadek TJ, Ziman A, Shoham S, Gebo KA, Bloch EM, Tobian AAR, Sullivan DJ, Gerber JM (2023). Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials. Transfusion, 63(9), 1639-1648. (Read full article)
    18. Ince D, Fiawoo S, Choudhury R, Cosgrove SE, Dobrzynski D, Gold H, Lee JH, Percival KM, Shulder S, Sony D, Spivak ES, Tamma PD, Nori P (2023). Epidemiology of Gram-Negative Bloodstream Infections in the United States: Results From a Cohort of 24 Hospitals. Open Forum Infect Dis, 10(7), ofad265. (Read full article)
    19. Timbrook TT, Prinzi AM, Spivak ES (2023). Diagnostic and antimicrobial stewardship workforce challenges: A crisis in combating antimicrobial resistance. Antimicrob Steward Healthc Epidemiol, 3(1), e60. (Read full article)
    20. Baksh S, Heath SL, Fukuta Y, Shade D, Meisenberg B, Bloch EM, Tobian AAR, Spivak ES, Patel B, Gerber J, Raval JS, Forthal D, Paxton J, Mosnaim G, Anjan S, Blair J, Cachay E, Currier J, Das P, Huaman M, Sutcliffe C, Yarava A, Casadevall A, Sullivan D, Hanley D, Gebo KA, CSSC-004 Consortium (2023). Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a randomized trial. J Infect Dis. (Read full article)
    21. Rock C, Abosi O, Bleasdale S, Colligan E, Diekema DJ, Dullabh P, Gurses AP, Heaney-Huls K, Jacob JT, Kandiah S, Lama S, Leekha S, Mayer J, Mena Lora AJ, Morgan DJ, Osei P, Pau S, Salinas JL, Spivak E, Wenzler E, Cosgrove SE (2021). Clinical Decision Support Systems to Reduce Unnecessary Clostridioides difficile Testing Across Multiple Hospitals. Clin Infect Dis, 75(7), 1187-1193. (Read full article)
    22. Vaughn VM, Giesler DL, Mashrah D, Brancaccio A, Sandison K, Spivak ES, Szymczak JE, Wu C, Horowitz JK, Bashaw L, Hersh AL (2022). Pharmacist gender and physician acceptance of antibiotic stewardship recommendations: An analysis of the reducing overuse of antibiotics at discharge home intervention. Infect Control Hosp Epidemiol, 44(4), 1-8. (Read full article)
    23. Wimmer MR, Schulz LT, Hamel AG, Schwei RJ, Fong K, Burgess DR, Brett M, Hale CM, Holubar M, Jain R, Larry R, Spivak ES, Newland H, Njoku J, Postelnick M, Walraven C, Pulia MS (2022). The impact of coronavirus disease 2019 (COVID-19) on the antimicrobial stewardship pharmacist workforce: A multicenter survey. Antimicrob Steward Healthc Epidemiol, 2(1), e56. (Read full article)
    24. Shah KS, Reyes-Miranda AE, Bradley SM, Breathett K, Das SR, Gluckman TJ, Gupta D, Leung DT, Mutharasan RK, Peterson PN, Spivak ES, Shah RU (2022). Clinical Trial Participation and COVID-19: a Descriptive Analysis from the American Heart Association's Get With The Guidelines Registry. J Racial Ethn Health Disparities. (Read full article)
    25. Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF (2022). Early Outpatient Treatment for Covid-19 with Convalescent Plasma. N Engl J Med. (Read full article)
    26. Webb BJ, Levin NM, Grisel N, Brown SM, Peltan ID, Spivak ES, Shah M, Stenehjem E, Bledsoe J (2022). Simple scoring tool to estimate risk of hospitalization and mortality in ambulatory and emergency department patients with COVID-19. PLoS One, 17(3), e0261508. (Read full article)
    27. Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF (2021). Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. (Read full article)
    28. Claeys KC, Trautner BW, Leekha S, Coffey KC, Crnich CJ, Diekema D, Fakih MG, Goetz MB, Gupta K, Jones MM, Leykum L, Liang SY, Pineles L, Pleiss A, Spivak ES, Suda KJ, Taylor J, Rhee C, Morgan DJ (2021). Optimal Urine Culture Diagnostic Stewardship Practice- Results from an Expert Modified-Delphi Procedure. Clin Infect Dis. (Read full article)
    29. Heil EL, Bork JT, Abbo LM, Barlam TF, Cosgrove SE, Davis A, Ha DR, Jenkins TC, Kaye KS, Lewis JS 2nd, Ortwine JK, Pogue JM, Spivak ES, Stevens MP, Vaezi L, Tamma PD (2021). Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process. Open Forum Infect Dis, 8(10), ofab434. (Read full article)
    30. Fowler VG, Jezek A, Spivak ES, Talkington K (2021). Urgent, Comprehensive Federal Action Needed To Stem Mortality and Medicare Costs Associated With Antimicrobial Resistance. Clin Infect Dis. (Read full article)
    31. Vaughn VM, Hersh AL, Spivak ES (2021). Antibiotic Overuse and Stewardship at Hospital Discharge: The Reducing Overuse of Antibiotics at Discharge (ROAD) Home Framework. Clin Infect Dis. (Read full article)
    32. Madaras-Kelly K, Hostler C, Townsend M, Potter EM, Spivak ES, Hall SK, Goetz MB, Nevers M, Ying J, Haaland B, Rovelsky SA, Pontefract B, Fleming-Dutra K, Hicks LA, Samore MH (2020). Impact of Implementation of the Core Elements of Outpatient Antibiotic Stewardship Within Veterans Health Administration Emergency Departments and Primary Care Clinics on Antibiotic Prescribing and Patient Outcomes. Clin Infect Dis, 73(5), e1126-e1134. (Read full article)
    33. Webb BJ, Buckel W, Vento T, Butler AM, Grisel N, Brown SM, Peltan ID, Spivak ES, Shah M, Sakata T, Wallin A, Stenehjem E, Poulsen G, Bledsoe J (2021). Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. Open Forum Infect Dis, 8(7), ofab331. (Read full article)
    34. Gibson EG, Pender M, Angerbauer M, Cook C, Jones B, Spivak AM, Spivak ES, Swaminathan S (2021). Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis. Open Forum Infect Dis, 8(7), ofab176. (Read full article)
    35. Fox ER, Shah M, Vinik R, Brown S, Buckel W, Webb B, Zarndt J, Evans M, Mesdaghi P, Imlay HN, Spivak ES (2021). Developing statewide remdesivir use criteria. Am J Health Syst Pharm, 78(8), 732-735. (Read full article)
    36. Rhodes NJ, Dairem A, Moore WJ, Shah A, Postelnick MJ, Badowski ME, Michienzi SM, Borkowski JL, Polisetty RS, Fong K, Spivak ES, Beardsley JR, Hale CM, Pallotta AM, Srinivas P, Schulz LT (2021). Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. Am J Health Syst Pharm, 78(7), 568-577. (Read full article)
    37. Rhoads JLW, Willson TM, Sutton JD, Spivak ES, Samore MH, Stevens VW (2019). Epidemiology, Disposition, and Treatment of Ambulatory Veterans With Skin and Soft Tissue Infections. Clin Infect Dis, 72(4), 675-681. (Read full article)
    38. Oliver MB, Fong K, Certain L, Spivak ES, Timbrook TT (2021). Validation of a Community-Acquired Pneumonia Score To Improve Empiric Antibiotic Selection at an Academic Medical Center. Antimicrob Agents Chemother, 65(2). (Read full article)
    39. Eudy JL, Pallotta AM, Neuner EA, Brummel GL, Postelnick MJ, Schulz LT, Spivak ES, Wrenn RH (2020). Antimicrobial Stewardship Practice in the Ambulatory Setting From a National Cohort. Open Forum Infect Dis, 7(11), ofaa513. (Read full article)
    40. Ciarkowski CE, Timbrook TT, Kukhareva PV, Edholm KM, Hatton ND, Hopkins CL, Thomas F, Sanford MN, Igumnova E, Benefield RJ, Kawamoto K, Spivak ES (2020). A Pathway for Community-Acquired Pneumonia With Rapid Conversion to Oral Therapy Improves Health Care Value. Open Forum Infect Dis, 7(11), ofaa497. (Read full article)
    41. Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, Spivak AM, Steinbach M, Blaylock RC, Avila SV, Hankey KG, Martins TB, Slev PR, Mannuel HD, Sajadi M, Rapoport AP, Atanackovic D (2020). Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv, 4(19), 4864-4868. (Read full article)
    42. Sutton JD, Stevens VW, Chang NN, Khader K, Timbrook TT, Spivak ES (2020). Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source. JAMA Netw Open, 3(10), e2020166. (Read full article)
    43. Timbrook TT, McKay L, Sutton JD, Spivak ES (2020). Disproportionality Analysis of Safety With Nafcillin and Oxacillin With the FDA Adverse Event Reporting System (FAERS). Antimicrob Agents Chemother, 64(3), e01818-19.
    44. Timbrook TT, McKay L, Sutton JD, Spivak ES (2020). Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS). Antimicrob Agents Chemother, 64(3). (Read full article)
    45. Sutton JD, Carico R, Burk M, Jones MM, Wei X, Neuhauser MM, Goetz MB, Echevarria KLSpivak ES, Cunningham FE Skin and Soft Tissue Infection Medication Use Evaluation Group (2020). Inpatient Management of Uncomplicated Skin and Soft Tissue Infections in 34 Veterans Affairs Medical Centers: A Medication Use Evaluation. . Open Forum Infect Dis, 7(1), ofz554.
    46. Sutton JD, Carico R, Burk M, Jones MM, Wei X, Neuhauser MM, Goetz MB, Echevarria KL, Spivak ES, Cunningham FE, Skin and Soft Tissue Infection Medication Use Evaluation Group (2020). Inpatient Management of Uncomplicated Skin and Soft Tissue Infections in 34 Veterans Affairs Medical Centers: A Medication Use Evaluation. Open Forum Infect Dis, 7(1), ofz554. (Read full article)
    47. Erickson RM, Tritle BJ, Spivak ES, Timbrook TT (2019). Impact of an Antimicrobial Stewardship Bundle for Uncomplicated Gram-Negative Bacteremia. . Open Forum Infect Dis, 6(12).
    48. Erickson RM, Tritle BJ, Spivak ES, Timbrook TT (2019). Impact of an Antimicrobial Stewardship Bundle for Uncomplicated Gram-Negative Bacteremia. Open Forum Infect Dis, 6(12), ofz490. (Read full article)
    49. Ihm C, Sutton JD, Timbrook TT, Spivak ES (2019). Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure. Open Forum Infect Dis, 6(6), ofz217.
    50. Ihm C, Sutton JD, Timbrook TT, Spivak ES (2019). Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure. Open Forum Infect Dis, 6(6), ofz217. (Read full article)
    51. Spivak ES (2019). Antibiotic Use in Dentistry-What We Know and Do Not Know. JAMA Netw Open, 2(5), e193881. (Read full article)
    52. Benefield RJ, Slechta ES, Gast CM, Spivak ES, Hanson KE, Alexander DP (2018). Comparison of the Drug-Drug Interaction Potential of Daptomycin in Combination with Rifampin in Healthy Adult Volunteers. Antimicrob Agents Chemother, 62(12). (Read full article)
    53. Buss BA, Baures TJ, Yoo M, Hanson KE, Alexander DP, Benefield RJ, Spivak ES (2018). Impact of a Multiplex PCR Assay for Bloodstream Infections With and Without Antimicrobial Stewardship Intervention at a Cancer Hospital. Open Forum Infect Dis, 5(10), ofy258.
    54. Buss BA, Baures TJ, Yoo M, Hanson KE, Alexander DP, Benefield RJ, Spivak ES (2018). Impact of a Multiplex PCR Assay for Bloodstream Infections With and Without Antimicrobial Stewardship Intervention at a Cancer Hospital. Open Forum Infect Dis, 5(10), ofy258. (Read full article)
    55. Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers HF (2017). Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting. Clin Infect Dis, 67(8), 1168-1174. (Read full article)
    56. Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers HF (2018). Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting. Clin Infect Dis, 67(8), 1168-1174.
    57. Benefield RJ, Slechta ES, Gast CM, Spivak ES, Hanson KE, Alexander DP (2018). Comparison of the drug-drug interaction potential of daptomycin in combination with rifampin in healthy adult volunteers. Antimicrob Agents Chemother, Epub ahead.
    58. Timbrook TT, Spivak ES, Hanson KE (2018). Current and Future Opportunities for Rapid Diagnostics in Antimicrobial Stewardship. Med Clin North Am, 102(5), 899-911. (Read full article)
    59. Spivak ES, Neuhauser MM, Zhang R, Goetz MB, Cunningham FE (2018). Reply to Johnson. Clin Infect Dis, 66(11), 1817. (Read full article)
    60. Sutton JD, Sayood S, Spivak ES (2018). Top Questions in Uncomplicated, Non-Staphylococcus aureus Bacteremia. Open Forum Infect Dis, 5(5), ofy087. (Read full article)
    61. Lindgren KE, Pelt CE, Anderson MB, Peters CL, Spivak ES, Gililland JM (2018). Corrigendum to 'A Chlorhexidine Solution Reduces Aerobic Organism Growth in Operative Splash Basins in a Randomized Controlled Trial' [Journal of Arthroplasty (2018) 211-215]. J Arthroplasty, 33(4), 1305. (Read full article)
    62. Spivak ES, Hanson KE (2018). Candida auris: an Emerging Fungal Pathogen. J Clin Microbiol, 56(2). (Read full article)
    63. Lindgren KE, Pelt CE, Anderson MB, Peters CL, Spivak ES, Gililland JM (2017). A Chlorhexidine Solution Reduces Aerobic Organism Growth in Operative Splash Basins in a Randomized Controlled Trial. J Arthroplasty, 33(1), 211-215. (Read full article)
    64. Spivak ES, Burk M, Zhang R, Jones MM, Neuhauser MM, Goetz MB, Cunningham FE, Management of Urinary Tract Infections Medication Use Evaluation Group, Management of Urinary Tract Infections Medication Use Evaluation Group (2017). Management of Bacteriuria in Veterans Affairs Hospitals. Clin Infect Dis, 65(6), 910-917. (Read full article)
    65. Spivak ES, Burk M, Zhang R, Jones MM, Neuhauser MM, Goetz MB, Cunningham FE (2017). Management of Bacteriuria in Veterans Affairs Hospitals. Clin Infect Dis, 65(6), 910-917.
    66. Goates C, Tsuha S, Working S, Carey J, Spivak ES (2017). Seronegative West Nile Virus Infection in a Patient Treated with Rituximab for Rheumatoid Arthritis. Am J Med, 130(6), e257-e258. (Read full article)
    67. Gruninger RJ, Johnson RA, Das SK, Nelson EJ, Spivak ES, Contreras JR, Faruque AS, Leung DT (2017). Socioeconomic Determinants of Ciprofloxacin-resistant Shigella Infections in Bangladeshi Children. Pathog Immun, 2(1), 89-101.
    68. Guan J, Spivak ES, Wilkerson C, Park MS (2016). Subdural Empyema in the Setting of Multimodal Intracranial Monitoring. World Neurosurg, 97, 749.e1-749.e6. (Read full article)
    69. Gruninger RJ, Johnson RA, Das SK, Nelson EJ, Spivak ES, Contreras JR, Faruque ASG, Leung DT (2017). Socioeconomic Determinants of Cipro-floxacin-Resistant Shigella Infections in Bangladeshi Children. Pathog Immun, 2(1), 89-101. (Read full article)
    70. Spivak ES, Cosgrove SE, Srinivasan A (2016). Measuring Appropriate Antimicrobial Use: Attempts at Opening the Black Box. Clin Infect Dis, 63(12), 1639-1644. (Read full article)
    71. Yarbrough PM, Kukhareva PV, Spivak ES, Hopkins C, Kawamoto K (2015). Evidence-based care pathway for cellulitis improves process, clinical, and cost outcomes. J Hosp Med, 10(12), 780-6. (Read full article)
    72. Yarbrough PM, Kukhareva PV, Spivak ES, Hopkins C, Kawamoto K (2015). Evidence-based care pathway for cellulitis improves process, clinical, and cost outcomes. J Hosp Med, 10(12), 780-6.
    73. Spivak ES, Kendall B, Orlando P, Perez C, De Amorim M, Samore M, Pavia AT, Hersh AL (2015). Evaluation of Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Hospital. Infect Control Hosp Epidemiol, 36(9), 1103-5. (Read full article)
    74. Spivak ES, Kendall B, Orlando P, Perez C, De Amorim M, Samore M, Pavia AT, Hersh AL (2015). Evaluation of Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Hospital. Infect Control Hosp Epidemiol, 36(9), 1103-5.
    75. Lynch L, Spivak ES (2015). The pregnant healthcare worker: fact and fiction. Curr Opin Infect Dis, 28(4), 362-8. (Read full article)
    76. Spivak ES, Kendall B, Orlando P, Perez C, De Amorim M, Samore M, Pavia AT, Hersh AL (2015 May). Evaluation of Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Hospital. Infect Control Hosp Epidemiol, 26, 1-3.
    77. Dufresne SF, Marr KA, Sydnor E, Staab JF, Karp JE, Lu K, Zhang SX, Lavalle C, Perl TM, Neofytos D (2014 Jun). Epidemiology of Candida kefyr in patients with hematologic malignancies. J Clin Microbiol, 52(6), 1830-7.
    78. Sydnor ER, Bova G, Gimburg A, Cosgrove SE, Perl TM, Maragakis LL (2012). Electronic Eye Faucets: Legionella spp. Contamination in Healthcare Settings. Infect Control Hosp Epidemiol, 33(3), 235-40.
    79. Emily RM Sydnor MD, MHS, Amy Greer PhD, Alicia P Budd MPH, Miriana Pehar RN, Supriya Munshaw PhD, Dionissios Neofytos MD, Trish M Perl MD, MSc, Alexandra Valsamakis MD, PhD (2012). An outbreak of human parainfluenza virus 3 infection in an outpatient hematopoietic stem cell transplantation clinic. Am J Infect Control, 40(7), 601-5.
    80. Sydnor ER, Lenhart A, Trollinger B, Avdic E, Maragakis LL, Carroll KC, Cosgrove SE (2011). Antimicrobial Prescribing Practices in Response to Different Clostridium difficile Diagnostic Methodologies. Infect Control Hosp Epidemiol, 32(11), 1133-6.
    81. Tamma PD, Turnbull AE, Milstone AM, Lehmann CU, Sydnor ER, Cosgrove SE (2011). Ventilator-associated tracheitis in children: does antibiotic duration matter? Clin Infect Dis, 52(11), 1324-31. (Read full article)
    82. Manabe YC, Campbell JD, Sydnor E, Moore RD (2007). Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr, 46(4), 456-62. (Read full article)

    Review

    1. Hartlage W, Imlay H, Spivak ES (2024). The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia. [Review]. Antimicrob Steward Healthc Epidemiol, 4(1), e214. (Read full article)
    2. Timbrook TT, Spivak ES, Hanson KE (2018). Current and Future Opportunities for Rapid Diagnostics in Antimicrobial Stewardship. [Review]. Med Clin North Am, 102(5), 899-911.
    3. Sutton JD, Sayood S, Spivak ES (2018). Top Questions in Uncomplicated, Non-Staphylococcus aureus Bacteremia. [Review]. Open Forum Infect Dis, 5(5), ofy087.
    4. Spivak ES, Hanson KE (2018). Candida auris: an Emerging Fungal Pathogen. [Review]. J Clin Microbiol, 56(2), e01588-17.
    5. Spivak ES, Cosgrove SE, Srinivasan A (Sep 2016). Measuring Appropriate Antimicrobial Use: Attempts at Opening the Black Box. [Review]. Clin Infect Dis, 63(12), 1639-1644.
    6. Lynch L, Spivak ES (2015 Aug). The pregnant healthcare worker: fact and fiction. [Review]. Curr Opin Infect Dis, 28(4), 362-8.
    7. Sydnor E, Perl TM (2014 Aug 27). Healthcare providers as sources of vaccine-preventable diseases. [Review]. Vaccine, 32(38), 4814-4822.
    8. Sydnor ER, Perl TM (2011). Hospital epidemiology and infection control in acute-care settings. [Review]. Clin Microbiol Rev, 24(1), 141-73. (Read full article)
    9. Spivak AM, Sydnor ER, Blankson JN, Gallant JE (2010). Seronegative HIV-1 infection: a review of the literature. [Review]. AIDS, 24(10), 1407-14. (Read full article)

    Commentary

    1. Sutton JD, Spivak ES (2022). Oral step-down with β-lactams for uncomplicated Enterobacterales bacteraemia. Clin Microbiol Infect, 29(4), 408-410. (Read full article)

    Case Report

    1. Goates C, Tsuha S, Working S, Carey J, Spivak ES (2017). Seronegative West Nile Virus Infection in a Patient Treated with Rituximab for Rheumatoid Arthritis. Am J Med, 130(6), e257-e258.

    Editorial

    1. Greenlee SB, Spivak ES (2023). Antimicrobial Stewardship: Reflections and the Road Ahead. Infect Dis Clin North Am, 37(4), xiii-xiv. (Read full article)
    2. Spivak ES (2019). Antibiotic Use in Dentistry-What We Know and Do Not Know. 2(5), e193881.

    Letter

    1. Advani SD, Schwartz IS, Spivak ES, Sutton JD (2020). Re: 'Antibiotic Treatment for 6 Days Versus 12 Days in Patients With Severe Cellulitis' by Cranendonk Et Al [Letter to the editor]. Clin Microbiol Infect, 26(5), 654-655.
    2. Advani SD, Schwartz IS, Spivak ES, Sutton JD (2019). Re: 'Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis' by Cranendonk et al. [Letter to the editor]. Clin Microbiol Infect, 26(5), 654-655. (Read full article)
    3. Fabre V, Spivak ES, Keller SC (2020). Viewing the Community-acquired Pneumonia Guidelines Through an Antibiotic Stewardship Lens [Letter to the editor]. Am J Respir Crit Care Med, 201(6), 745-746.
    4. Fabre V, Spivak ES, Keller SC (2019). Viewing the Community-acquired Pneumonia Guidelines through an Antibiotic Stewardship Lens. [Letter to the editor]. Am J Respir Crit Care Med, 201(6), 745-746. (Read full article)
    5. Tritle BJ, Timbrook TT, Fisher MA, Spivak ES (2020). Penicillin as a Potential Agent for Dual β-Lactam Therapy for Enterococcal Endocarditis [Letter to the editor]. Clin Infect Dis, 70(6), 1263-1264.
    6. Tritle BJ, Timbrook TT, Fisher MA, Spivak ES (2019). Penicillin as a Potential Agent for Dual β-Lactam Therapy for Enterococcal Endocarditis. [Letter to the editor]. Clin Infect Dis, 70(6), 1263-1264. (Read full article)
    7. Babbel D, Sutton J, Rose R, Yarbrough P, Spivak ES (2018). Application of the DRIP Score at a Veterans Affairs Hospital. [Letter to the editor]. Antimicrob Agents Chemother, 62(3). (Read full article)
    8. Babbel D, Sutton J, Rose R, Yarbrough P, Spivak ES (2018). Application of the DRIP Score at a Veterans Affairs Hospital [Letter to the editor]. Antimicrob Agents Chemother, 62(3), e02277-17.
    9. Spivak ES, Cosgrove SE, Srinivasan A (2017). Reply to Schouten et al. [Letter to the editor]. Clin Infect Dis, 64(9), 1296. (Read full article)

  • News & Podcasts

    News

    Podcasts